|Bid||5.70 x 1100|
|Ask||5.71 x 900|
|Day's range||5.54 - 5.96|
|52-week range||2.87 - 17.85|
|Beta (5Y monthly)||1.16|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.78|
Biotech company Bluebird Bio (NASDAQ: BLUE) is currently riding high. Despite these accomplishments, Bluebird is still a tiny company with a market cap of just $475 million. Of note, Skysona had previously earned marketing authorization in Europe, but Bluebird exited the European market last year for reasons that may also prove to be a challenge in the U.S. (more on that in a bit).
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.